EGFR and lung adenocarcinoma: Given the need for clinical validation of any updated analysis tool, our main objectives were to identify differences in serial changes of various CT-based parameters in patients with lung adenocarcinoma scheduled to undergo surgical resection after neoadjuvant therapy, and to correlate those changes with pathologic responses, focused on their relationship with different neoadjuvant therapeutic options, particularly of EGFR-TKI and concurrent chemoradiation therapy (CCRT) settings.